MDT Stock Recent News
MDT LATEST HEADLINES
MDT delivers strong earnings in the fiscal 2025 third quarter, with significant improvements in both gross and operating margins.
Tuesday, Medtronic Plc MDT reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion.
Medtronic (MDT) came out with quarterly earnings of $1.39 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.30 per share a year ago.
Medtronic said it is “starting to see the results” of its investment in new products.
Medtronic beat Wall Street estimates for quarterly profit on Tuesday, on strong demand for its heart and diabetes devices.
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland , Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organic GAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7% Company reiterates full year revenue and EPS guidance Cardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) products U.S. Centers for Medicare and Medicaid (CMS) announced coverage for Renal Denervation for the treatment of Hypertension expected to become final on or before October 11, 2025 Financial Results Medtronic reported Q3 worldwide revenue of $8.292 billion, an increase of 2.5% as reported and 4.1% on an organic basis.
Medtronic: Several Reasons For Optimism Before The Upcoming Earnings Release
In the closing of the recent trading day, Medtronic (MDT) stood at $92.20, denoting a +0.93% change from the preceding trading day.
I'm about to get a big cash infusion in my portfolio. Last year, private equity giant Blackstone agreed to buy one of my holdings, Retail Opportunity Investments Corp. , in an all-cash deal.
Beyond analysts' top -and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended January 2025.